Birgin et al. document how state-driven stigma, criminalisation, and abuse create gendered barriers in access to services and drive women imprisonment, prompting mobilisation in resistance.
IDPC and the GDPO analyse the limitations of the data and methodologies in the report, and explore the implications of these shortcomings for drug policy in Africa.
David Restrepo critically reviews Colombia’s 2020 legislative proposal to regulate the coca leaf and cocaine markets by providing qualitative analysis of the regulatory regime proposed, its effects across the supply system, and the associated benefit and cost outcomes for Colombia.
ReLeaf Malta and Moviment Graffitti outline a vision to redress prior abuses, embed drug policy in human rights and harm reduction, and undo persisting discriminations.
Boyd et al. shed light on the harmful impact of punitive and stigmatising policies and practices on mothers' overdose risk, concluding on the need to expand support and care in the community.
The Canadian Centre on Substance Use and Addiction summarises 6 studies assessing key impacts and pending questions brought about by the legal regulation of cannabis in the country.
Jones et al. find a correlation between lifetime psilocybin use and lowered odds of opioid dependence, calling for further studies to determine whether this relationship is causal.
This briefing paper by IDPC and AFRILAW presents new evidence on the physical and mental violence faced by people who use drugs in Nigeria, both at the hands of law enforcement agents and in drug treatment centres.
Transform provides a summary of key available data on which to assess the effectiveness of the MDA 1971, covering impacts in terms of the criminal legal system, health and trends in drug markets.
Harm Reduction International provides an update on legislative, policy and practical developments related to the use of capital punishment for drug offences.
The INCB reviews the functioning of the international drug control system and includes an analysis of the availability of controlled substances for medical and scientific purposes, particularly in humanitarian emergencies.